Multiples Private Equity Fund’s investment in BDR Pharmaceuticals International Private Limited
JSA advised and represented Multiples Private Equity Fund (“Multiples”) in an investment of INR 685 crores by a consortium of investors led by Multiples for a 9.3% stake in BDR Pharmaceuticals International Private Limited (“BDR Pharma”). This is the first investment into the company.
BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores. The company focuses on therapeutic segments such as oncology and critical care with a growing presence in dermatology and gynaecology. BDR Pharma shot to fame during Covid-19 for developing copies of antivirals such as remdesivir, favipiravir, molnupiravir and lyophilized amphotericin b injection.
JSA team comprised
Anand Lakra Lead Partner
Niharika Mepani Principal Associate
Ami Shah Associate
Jinay Shah Associate
Sonakshi Verma Associate
JSA Employment team
Maneesh Upadhyay Partner
Ashrafi Ginwalla Senior Associate
JSA competition team
Vaibhav Choukse Partner & Head of Practice (Competition Law)